Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Administration of ALA vs Progesterone for the Subchorionic Hematoma Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 24-37~* Gestational week: 7- 12~* Evidence of threatened miscarriage (pelvic pain with or without vaginal bleeding)~* Ultrasound evidence of subchorionic hematoma~Exclusion Criteria:~* Lack of fetus~* Absence of fetal heart tone~* Uterine anomaly or fetal anomaly~* Presence of multiple pregnancy~* Gestation pathology~* Therapies with anti-coagulants or anti-hypertensive drugs

- Gender: FEMALE
- Minimum Age: 24 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- Lipoic acid (Type: EXPERIMENTAL): vaginal capsules of lipoic acid (10 mg, one capsule per day)
- Progesterone (Type: ACTIVE_COMPARATOR): Vaginal soft gel of progesterone (200 mg, two capsules per day)

Based on this trial design, predict the completion outcome and termination type (if applicable).